An Evaluation of the Effect of the Erchonia FX-405 Laser as an Adjunctive Treatment of Periodontitis
Erchonia Corporation · NCT06656325
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 22–75 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 70
- US sites recruiting
- 2
- Study start
- January 1, 2025
- Record last updated
- May 18, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this clinical study is to determine the effectiveness of the Erchonia® FX-405 (manufactured by Erchonia Corporation (the Company) in providing a noninvasive adjunctive treatment in combination with periodontal scaling and root planing for improving the treatment of periodontal disease.
Being studied: Erchonia® FX405; Placebo Laser
Conditions: Periodontal Diseases; Periodontitis; Gum Disease
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Subject has voluntarily signed a written informed consent form.
- Male or female 22 to 75 years of age, inclusive.
- Subject has no evidence of Localized Aggressive Periodontitis.
- Tooth loss due to periodontitis of ≤ 4 teeth.
- Two or more teeth with the following characteristics: Non 3rd molar, Periodontitis: Stage III (Severity) according to the Interdental CAL (at site of greatest loss) and RBL, as classified by the American Academy of Periodontology (AAP), No evidence of caries, No abscess infection, No previous periodontal surgery within the prior 12 months
- Subject agrees to adhere to study provided home care instructions to maintain adequate oral hygiene during the study duration.
- Subject agrees to refrain from the use of smokeless chewing tobacco for the study duration.
- Subject agrees to refrain from exceeding 40 milligrams per day of inhaled nicotine, encompassing cigarettes, electronic cigarettes, and cigars.
- Subject agrees to refrain from engaging in any other treatments for his or her periodontitis that is outside the scope of this study during his or her participation in this study
Exclusion Criteria
- Gingival recession which may be genetic, induced secondary to orthodontic treatment, induced secondary to frenulum attachments, or present as a result of dental malocclusion.
- History of oral cancer or HIV in the last 6 months
- Pregnant or intending to become pregnant in the next 8 months.
- Sensitivity to, or contraindication for, light therapy.
- Currently enrolled in a clinical study of an investigational drug or device.
Recruiting US locations
805 Dentistry
Thousand Oaks, CA 91360
Site contact: Dar Radfar, DDS · 805-273-8857 · darradfar@gmail.com
Acton Dental Associates
Acton, MA 01720
Site contact: Eric Block, DMD · 978-881-5826 · info@actondental.com